Quantitative analysis for Genmab A/S (GMAB) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (64.0) (grade B). 30 signals analyzed (25 differentiated alt-data).
GMAB stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $26.29 | $25.72 | $26.11 |
| 2026-05-11 | $26.60 | $25.92 | $26.18 |
| 2026-05-21 | $27.19 | $26.63 | $27.05 |
| 2026-06-03 | $23.91 | $23.62 | $23.88 |
| 2026-06-15 | $25.20 | $24.51 | $24.58 |
| 2026-06-26 | $26.17 | $25.33 | $26.12 |
| 2026-07-09 | $29.80 | $28.92 | $29.78 |
| 2026-07-21 | $28.55 | $27.98 | $28.36 |
| 2026-07-31 | $28.92 | $28.24 | $28.87 |
| 2026-08-12 | $31.61 | $30.69 | $31.42 |
| 2026-08-24 | $33.32 | $32.74 | $33.02 |
| 2026-09-03 | $34.66 | $34.08 | $34.41 |
How Genmab A/S stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ASND | Ascendis Pharma A/S | $14.9B | — |
| SNN | Smith & Nephew plc | $13.2B | — |
| BNTX | BioNTech SE | $22.9B | — |
| FMS | Fresenius Medical Care AG & Co. KGaA | $12.0B | — |
View all Health Care stocks by valuation and signals →
Genmab A/S (GMAB) scores Buy (64.0), with no measured dimension below 79. Its highest are technicals at 85, analyst consensus at 79, across 2 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| technicals | 85 |
| analyst consensus | 79 |
StoQuant analyzes 30 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Genmab A/S (GMAB): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/GMAB"><img src="https://stoquant.com/badge/GMAB.svg" alt="Genmab A/S (GMAB) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.